For
Older Americans, Health Bill Will Bring Savings and ‘Peace of Mind’
Starting in 2025, Medicare recipients
with prescription drug coverage will not have to pay more than $2,000 annually
for medications, a significant savings for some.
By Sheryl
Gay Stolberg and Noah
Weiland
Aug. 10, 2022
WASHINGTON — After Pete Spring was
diagnosed with dementia in 2016, he and his wife emptied their checking account
in part to pay for his prescription drugs, then ran through $60,000 in pension
payments before resorting to a charge card to help make sure Mr. Spring had the
heart and Alzheimer’s medications he needed to survive — just two of the 11
drugs he took.
Mr. Spring, of Marietta, Ga., died in
April, before the unveiling of the tax, climate and health bill that the Senate
passed over the weekend. The measure aims to lower the cost of prescription
drugs for people on Medicare, like him; his wife, Gretchen Van Zile, has been
left to look back on what felt like an outrageous injustice.
“Here
seniors are in their golden years,” said Ms. Van Zile, 74, “and the only people
seeing gold are the pharmaceutical companies.”
Nearly
49 million people, most of them older Americans, get prescription drug coverage
through Medicare, yet many find that it does not go very far. Low-income
people qualify for government
subsidies, so those in the middle class — people like Mr. Spring and
Ms. Van Zile — are hit hardest by high drug costs.
The Senate bill, which the House is
expected to pass on Friday, then send to President Biden’s desk, could save
many Medicare beneficiaries hundreds, if not thousands of dollars a year. Its
best-known provision would empower Medicare to negotiate prices with drug
makers with the goal of driving down costs — a move the pharmaceutical industry
has fought for years, and one that experts said would help lower costs for
beneficiaries.
But the legislation would also take
more direct steps to keep money in people’s pocketbooks, though they would be
phased in over time.
Beginning
next year, insulin co-payments for Medicare recipients would be capped at $35 a
month. As of 2024, those with costs high enough to qualify for the program’s
“catastrophic coverage” benefit would no longer have to pick up 5 percent of
the cost of every prescription. And starting in 2025, out-of-pocket costs for
prescription medicines would be capped at $2,000 annually.
“This
is a huge policy change and one that has been a long time coming,” said Dr.
Stacie Dusetzina, an associate professor of health policy at Vanderbilt
University. “For people needing high-cost drugs, this will provide significant
financial relief.”
Between
2009 and 2018, the average price more than doubled for
brand-name prescription drugs in Medicare Part D, the program that covers
products dispensed by pharmacies, the Congressional Budget Office found.
Between 2019 and 2020, price increases outpaced inflation for half of all drugs covered
by Medicare, according to an analysis from the Kaiser Family Foundation.
Perhaps no drug has been talked about
as much as insulin, the diabetes medication that is more than 100 years old.
Prices for insulin and its analogues have risen so fast that many diabetes
patients who rely on the drug put themselves at risk by taking less than is prescribed to cut costs.
A 2020 commentary in
the medical journal Mayo Clinic Proceedings reported that one vial of Humalog,
a commonly prescribed insulin analogue, cost $21 in 1999 and $332 in 2019 — an
increase of well over 1,000 percent. (Amid congressional scrutiny, the drug’s
maker, Eli Lilly, promised in 2019 to market a lower-cost generic.)
More than three million Medicare
beneficiaries take one of the 42 different types of insulin that are covered by
Medicare, according to an estimate by the Kaiser Family Foundation, which found
that the average out-of-pocket cost is
$54 a month. But for some people, the costs are much higher.
Evelyn Poay, 82, of Merrick, N.Y.,
spends more than $1,200 every three months on four different diabetes
medicines, including Humalog and another type of injectable insulin, which she
has been taking for about 30 years.
She
still works as a part-time bookkeeper and counts herself as fortunate. “It’s
not a question of do I eat or do I take my medicine,” she said.
But
she worries about other people, including her own grandchildren, three of whom
also have diabetes. Democrats tried to apply the bill’s proposed $35 co-payment
to all insulin prescriptions, including those covered by private insurers. But
Republican senators forced the removal of that language — even though
seven of them wanted to keep it in the bill.
To hear the voices of older Americans
who confront high drug costs month in and month out is to hear fear and worry,
anger and stress. Many say they are figuring out how to get by, skipping
vacations and other niceties for which they saved.
For Kim Armbruster, 65, who recently
retired after a 40-year nursing career, keeping down the costs of her
medications for diabetes, psoriatic arthritis and Graves’ disease, an
autoimmune disorder affecting the thyroid, has been a scramble since she
started on Medicare in March.
Ms. Armbruster, of Cary, Ill., said she
had saved extra insulin from prescriptions filled when she had commercial
insurance, enough to keep costs down before a monthly cap kicks in. But her
other conditions have caused immense financial strain.
By June, she had reached Medicare’s
threshold for catastrophic coverage after paying more than $7,000 for Enbrel, a
drug she takes for the arthritis; Synthroid, which she takes for Graves’
disease; Eliquis, for atrial fibrillation, insulin and her insulin pump.
“It’s all about thinking ahead, looking
for alternatives and strategizing the home budget to be able to take the
necessary meds,” she said. Learning to keep up with costs, she added, had been
like “baptism by fire, to learn everything I can possibly learn about it to
maneuver drug costs and stay healthy without complications.”
The
carousel of medications taken by Mr. Spring, the dementia patient who died in
April, included eye-popping price tags for drugs including Eliquis, for a heart
condition, and Namenda, an Alzheimer’s drug. Mr. Spring also took an
antidepressant and medications to dull the side effects from Namenda.
Those
drugs ran the couple around $1,000 a month. Had the $2,000 annual out-of-pocket
cap been in place when her husband was alive, Ms. Van Zile said, they would
have reached it by March every year. Ms. Van Zile retired from her job working
for Fulton County in Georgia so that she could take care of her husband,
further cramping their savings.
“His sense of humor put a smile on my
face every day,” she said. “The bitter aspect of it was the financial stress.”
Democrats have been promising for years
to lower the cost of prescription drugs. So have some Republicans, including
former President Donald J. Trump. But the Senate bill passed along party lines,
without any Republican votes. In the 50-50 Senate, Vice President Kamala Harris
broke the tie vote.
Republicans, and the pharmaceutical
industry, insist that the measure will stifle innovation and reverse progress
on therapies and treatments, including those for cancer care — a high priority
for Mr. Biden. The industry’s main trade group, PhRMA, says the bill, which
imposes stiff penalties on companies that refuse to negotiate, amounts to
government price setting — not negotiation.
At a media briefing last month, Stephen J. Ubl, the
chief executive of PhRMA, warned that Democrats were “about to make a historic
mistake that will devastate patients desperate for new cures.”
But backers of the measure say new
treatments are meaningless if patients can’t afford them. The promise of
Medicare, enacted in 1965, has always been that it would take care of older
Americans. The prescription drug benefit was not added until 2003.
It
includes the provision for catastrophic coverage, in which the government picks
up the full cost of medicines — except for 5 percent, paid by the patient —
after an individual spends $7,050 a year out of pocket. The Kaiser Family
Foundation says that 1.3 million Medicare beneficiaries hit the catastrophic
threshold each year; 1.4 million have out-of-pocket costs of $2,000 or more.
“You
rarely hear people complain about turning age 65 and going on Medicare; it’s
often a relief,” said Larry Levitt, the foundation’s executive vice president
for health policy. “But the way Medicare now works, there can be some nasty
surprises for people with very high drug expenses, and this bill will provide a
lot of relief.”
A study conducted by Dr. Dusetzina
highlighted how the middle class gets squeezed. She examined 17,076 new
prescriptions issued between 2012 and 2018 for Part D beneficiaries, and found
that those receiving subsidies were nearly twice as likely to obtain the
prescribed drug within 90 days as those without subsidies.
Among those who did not qualify for
subsidies, 30 percent of all prescriptions for cancer drugs went unfilled, as
did more than 50 percent of prescriptions to treat immune system disorders or
high cholesterol.
Patti Kellerhouse, a 64-year-old in
Henderson, Nev., was diagnosed with metastatic breast cancer in 2017 that had
spread to her liver. On long-term disability through her employer, she had paid
$10 a month out of pocket for the oral cancer treatment she needed. But when
she transitioned to a Medicare Advantage plan, the medication cost more than
$3,100 for the first month.
While
she has been able to afford the price jump, it has stressed her financial
planning. She is saving money for a new car, among other things. She said she
has daughters and grandchildren whom she would like to continue supporting.
Bob
Miller was prescribed Betaseron, a brand-name drug that cost more than $10,000
a year. He said he stopped taking it in 2016, citing the high expense.Credit...Jenn Ackerman for The
“I
worked hard my whole life,” she said. “These are high co-payments. They
shouldn’t happen when you’re at retirement age.
Many
Americans make tough choices about whether to continue taking drugs they need.
Bob Miller, a 71 year-old multiple sclerosis patient in Prior Lake, Minn., is
among them.
Every other day for 12 years, Mr.
Miller took Betaseron, a brand-name prescription drug that can delay the
progression of his disease by staving off flare-ups of numbness, muscle
stiffness and other symptoms that can leave patients worse off than they were
before. But the drug was expensive; even with his Medicare insurance, it cost more
than $10,000 a year.
So he quit taking the drug in 2016
after consulting with his doctors, who told him he could “roll the dice” and
survive without it — at least for the time being. Since then, he has lived with
the unsettling worry that he is gambling with his own health.
“In the background, you don’t know
what’s going on,” Mr. Miller said. “There might still be some damage being done
to my nerve fibers.”
When
a neurologist recently told him it might help to go back on a disease-modifying
drug, Mr. Miller told him he would like to, if not for the prohibitive cost.
The new legislation, he said, will deliver something he has been longing for:
“Peace of mind.”
Sheryl Gay Stolberg
is a Washington Correspondent covering health policy. In more than two decades
at The Times, she has also covered the White House, Congress and national
politics. Previously, at The Los Angeles Times, she shared in two Pulitzer
Prizes won by that newspaper’s Metro staff. @SherylNYT
Noah Weiland is a
health reporter in the Washington bureau. He was part of a team that won a
Pulitzer Prize for its coverage of Covid-19 in 2020.
